Collectively, the findings indicated that antiangiogenesis could be a promising antitumor strategy for NPC treatment and the PI3K/Akt/mTOR–HIF-1α/VEGF signaling pathway axis could be a potential target for antitumor drug screening. This evidence concerns the gene AKT1 and nasopharyngeal carcinoma.